Dapagliflozin for Long COVID Syndrome

Launched by OTTAWA HEART INSTITUTE RESEARCH CORPORATION · Mar 31, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medication called dapagliflozin to see if it can help people suffering from long COVID syndrome. Long COVID can cause ongoing symptoms long after the initial COVID-19 infection, and this trial aims to find out if dapagliflozin can improve these symptoms. The study will involve randomly assigning participants to receive either dapagliflozin or a placebo (which looks like the medication but has no active ingredients) for a period of 12 months.

To be eligible for the trial, participants must be at least 18 years old and have had a positive COVID-19 test or a diagnosis of COVID-19 by a healthcare provider. They should also have new or ongoing symptoms that started at least 12 weeks after their infection and have lasted for at least 8 weeks. Certain conditions, like a history of diabetes or pregnancy, may prevent someone from participating. If you join the study, you will have regular check-ins, and your health will be monitored throughout the year to see how you respond to the treatment. It's important to note that this trial is not yet recruiting participants, so there will be more information available soon for those who are interested.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years of age or older and willing and able to provide informed consent
• • Patients with a history of positive COVID-19 test (polymerase chain reaction or rapid test) or have been diagnosed with COVID-19 by a health care provider.
• • New or persistent symptoms at least 12 weeks from infection and present for at least 8 weeks that is not explained by an alternative diagnosis (64).
• • Women of childbearing potential (WOCBP) who, if sexually active, are willing to use to use at least one highly effective methods of contraception throughout the study.
• Exclusion Criteria:
• • History of diabetes
• • Prior heart failure
• • Weight loss treatment with glucagon-like peptide-1 receptor agonists (e.g. liraglutide, semaglutide)
• • Pregnancy or planned pregnancy in the next 12 months. We will ask WOCBP about the possibility of pregnancy at the time of screening and if so, then pregnancy testing will be offered. If testing is declined in this instance, then they will be excluded from the study.
• • Women who are breastfeeding
• • Severe renal impairment (eGFR\<30mL/min1.73m2)
• • Known history of allergy or hypersensitivity to dapagliflozin
• Exclusion for optional MRI portion of the protocol:
• • - Any contraindication to MRI